Bristol Myers Squibb reports 51.00 percent lower risk for Bristol Myers Squibb stock
Published on 10/12/2026 at 11:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- Bristol Myers Squibb reported a 51.00 percent reduction in progression or death risk for ZENBEXUS in an 800-patient Phase 3 study.
- The trial showed median progression-free survival of 42 months versus 20 months for standard care.
- Bristol Myers Squibb stock was at EUR 52.91 at Lang & Schwarz on October 12, 2026, while third-quarter results are scheduled for October 29, 2026.
Bristol Myers Squibb (ISIN US1101221083) reported a 51.00 percent reduction in the risk of disease progression or death for ZENBEXUS in an 800-patient Phase 3 study announced on October 8, 2026. According to Bristol Myers Squibb, the treatment produced median progression-free survival of 42 months, compared with 20 months for the standard-care combination.
ZENBEXUS delivers a measurable gain
The result came from the EXCALIBER-RRMM study of ZENBEXUS with daratumumab and dexamethasone in relapsed or refractory multiple myeloma. The hazard ratio was 0.49, while median follow-up reached 23 months, giving the company a quantified clinical result rather than an early laboratory signal.
The trial also adds commercial importance to ZENBEXUS because Bristol Myers Squibb said the findings build on the treatment's earlier minimal residual disease response data. Safety remains a material consideration: the company reported serious adverse reactions in 58.30 percent of patients receiving ZENBEXUS.
Revenue and analyst targets set the test
The latest reported second-quarter 2026 revenue was USD 12.97 billion, up 5.70 percent year over year, while diluted earnings per share reached USD 1.62. MarketBeat reported that Bank of America cut its target from USD 71.00 to USD 66.00 on October 9, 2026, while the source cited a Hold consensus and a USD 64.96 average target.
The next scheduled company milestone is the third-quarter 2026 results announcement on October 29, 2026. According to Bristol Myers Squibb, executives will discuss the figures during an 8:00 a.m. ET conference call.
Stock price and upcoming results
Bristol Myers Squibb stock was trading at EUR 52.91 at Lang & Schwarz on October 12, 2026 at 11:35 a.m. CEST. The scheduled October 29 results date gives the market a defined checkpoint for judging whether the clinical progress is translating into operating momentum.
The further course of trading is shown by the continuously updated real-time quote of Bristol Myers Squibb stock.
Bristol Myers Squibb stock facts
- Company: Bristol-Myers Squibb Company
- ISIN: US1101221083
- Ticker: BMY
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 12, 2026, 11:35 a.m. CEST): EUR 52.91
- Market capitalization: USD 120.8 billion (as of October 9, 2026)
- 52-week range: USD 42.52-68.64 (as of October 9, 2026)
Market context: Market report S&P 500.
